x
|
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
¨
|
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
Delaware
(State
or Other Jurisdiction of Incorporation or Organization)
|
75-3142681
(I.R.S.
Employer Identification No.)
|
811
Hansen Way, Palo Alto, California 94303
(Address
of Principal Executive Offices and Zip Code)
|
|
(650)
846-2900
(Registrant’s
telephone number, including area code)
|
|
Not
Applicable
(Former
name, former address and former fiscal year, if changed since last
report)
|
4
|
||||
4
|
||||
4
|
||||
5
|
||||
6
|
||||
7
|
||||
37
|
||||
58
|
||||
60
|
||||
61
|
||||
61
|
||||
61
|
||||
61
|
||||
61
|
||||
61
|
||||
61
|
||||
62
|
March
28,
|
September
28,
|
|||||||
2008
|
2007
|
|||||||
Assets
|
||||||||
Current
Assets:
|
||||||||
Cash
and cash equivalents
|
$ | 20,241 | $ | 20,474 | ||||
Restricted
cash
|
1,790 | 2,255 | ||||||
Accounts
receivable, net
|
50,719 | 52,589 | ||||||
Inventories
|
66,861 | 67,447 | ||||||
Deferred
tax assets
|
9,948 | 9,744 | ||||||
Prepaid
and other current assets
|
3,787 | 4,639 | ||||||
Total
current assets
|
153,346 | 157,148 | ||||||
Property,
plant, and equipment, net
|
64,819 | 66,048 | ||||||
Deferred
debt issue costs, net
|
5,728 | 6,533 | ||||||
Intangible
assets, net
|
80,201 | 81,743 | ||||||
Goodwill
|
162,535 | 161,573 | ||||||
Other
long-term assets
|
796 | 3,177 | ||||||
Total
assets
|
$ | 467,425 | $ | 476,222 | ||||
Liabilities
and stockholders’ equity
|
||||||||
Current
Liabilities:
|
||||||||
Current
portion of long-term debt
|
$ | 2,000 | $ | 1,000 | ||||
Accounts
payable
|
21,849 | 21,794 | ||||||
Accrued
expenses
|
26,045 | 26,349 | ||||||
Product
warranty
|
4,952 | 5,578 | ||||||
Income
taxes payable
|
5,100 | 8,748 | ||||||
Advance
payments from customers
|
11,655 | 12,132 | ||||||
Total
current liabilities
|
71,601 | 75,601 | ||||||
Deferred
income taxes
|
26,310 | 28,394 | ||||||
Long-term
debt, less current portion
|
234,623 | 245,567 | ||||||
Other
long-term liabilities
|
2,120 | 754 | ||||||
Total
liabilities
|
334,654 | 350,316 | ||||||
Commitments
and contingencies
|
||||||||
Stockholders’
equity
|
||||||||
Common
stock ($0.01 par value, 90,000 shares authorized;
16,485 and 16,370 shares issued and
outstanding)
|
165 | 164 | ||||||
Additional
paid-in capital
|
70,165 | 68,763 | ||||||
Accumulated
other comprehensive (loss) income
|
(2,265 | ) | 937 | |||||
Retained
earnings
|
64,706 | 56,042 | ||||||
Total
stockholders’ equity
|
132,771 | 125,906 | ||||||
Total
liabilities and stockholders' equity
|
$ | 467,425 | $ | 476,222 |
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
March 28,
2008
|
March 30,
2007
|
March 28,
2008
|
March 30,
2007
|
|||||||||||||
Sales
|
$ | 94,804 | $ | 88,444 | $ | 180,714 | $ | 172,167 | ||||||||
Cost
of sales
|
66,738 | 60,739 | 128,512 | 117,881 | ||||||||||||
Gross
profit
|
28,066 | 27,705 | 52,202 | 54,286 | ||||||||||||
Operating
costs and expenses:
|
||||||||||||||||
Research
and development
|
2,930 | 2,352 | 5,654 | 4,243 | ||||||||||||
Selling
and marketing
|
5,328 | 4,799 | 10,500 | 9,628 | ||||||||||||
General
and administrative
|
5,492 | 5,846 | 11,645 | 10,250 | ||||||||||||
Amortization
of acquisition-related intangible assets
|
781 | 546 | 1,562 | 1,094 | ||||||||||||
Net
loss on disposition of fixed assets
|
41 | 40 | 75 | 58 | ||||||||||||
Total
operating costs and expenses
|
14,572 | 13,583 | 29,436 | 25,273 | ||||||||||||
Operating
income
|
13,494 | 14,122 | 22,766 | 29,013 | ||||||||||||
Interest
expense, net
|
4,805 | 5,275 | 9,617 | 10,614 | ||||||||||||
Loss
on debt extinguishment
|
393 | - | 393 | - | ||||||||||||
Income
before income taxes
|
8,296 | 8,847 | 12,756 | 18,399 | ||||||||||||
Income
tax expense
|
2,142 | 3,087 | 4,092 | 6,804 | ||||||||||||
Net
income
|
$ | 6,154 | $ | 5,760 | $ | 8,664 | $ | 11,595 | ||||||||
Other
comprehensive income, net of tax
|
||||||||||||||||
Net
unrealized loss on cash flow hedges
|
(2,001 | ) | (17 | ) | (3,202 | ) | (406 | ) | ||||||||
Comprehensive
income
|
$ | 4,153 | $ | 5,743 | $ | 5,462 | $ | 11,189 | ||||||||
Earnings
per share - Basic
|
$ | 0.38 | $ | 0.35 | $ | 0.53 | $ | 0.72 | ||||||||
Earnings
per share - Diluted
|
$ | 0.35 | $ | 0.32 | $ | 0.49 | $ | 0.66 | ||||||||
Shares
used to compute earnings per share - Basic
|
16,387 | 16,253 | 16,379 | 16,161 | ||||||||||||
Shares
used to compute earnings per share - Diluted
|
17,656 | 17,730 | 17,744 | 17,646 |
Six Months Ended
|
||||||||
March
28,
|
March
30,
|
|||||||
2008
|
2007
|
|||||||
Cash
flows from operating activities
|
||||||||
Net
cash provided by operating activities
|
$ | 10,439 | $ | 6,299 | ||||
Cash
flows from investing activities
|
||||||||
Capital
expenditures
|
(2,558 | ) | (5,347 | ) | ||||
Proceeds
from adjustment to acquisition purchase price
|
1,615 | - | ||||||
Capitalized
expenses relating to potential business acquisition
|
- | (119 | ) | |||||
Payment
of patent application fees
|
(147 | ) | - | |||||
Net
cash used in investing activities
|
(1,090 | ) | (5,466 | ) | ||||
Cash
flows from financing activities
|
||||||||
Repayments
of debt
|
(10,000 | ) | (5,000 | ) | ||||
Proceeds
from issuance of common stock to employees
|
418 | 398 | ||||||
Proceeds
from exercise of stock options
|
- | 542 | ||||||
Excess
tax benefit on stock option exercises
|
- | 679 | ||||||
Net
cash used in financing activities
|
(9,582 | ) | (3,381 | ) | ||||
Net
decrease in cash and cash equivalents
|
(233 | ) | (2,548 | ) | ||||
Cash
and cash equivalents at beginning of period
|
20,474 | 30,153 | ||||||
Cash
and cash equivalents at end of period
|
$ | 20,241 | $ | 27,605 | ||||
Supplemental
cash flow disclosures
|
||||||||
Cash
paid for interest
|
$ | 8,293 | $ | 10,707 | ||||
Cash
paid for income taxes, net of refunds
|
$ | 8,722 | $ | 10,495 |
1.
|
The
Company and a Summary of its Significant Accounting
Policies
|
2.
|
Recently
Issued Accounting Standards
|
3.
|
Supplemental
Balance Sheet Information
|
|
March
28,
|
September
28,
|
||||||
2008
|
2007
|
|||||||
Accounts
receivable
|
$ | 51,108 | $ | 52,678 | ||||
Less:
Allowance for doubtful accounts
|
(389 | ) | (89 | ) | ||||
Accounts
receivable, net
|
$ | 50,719 | $ | 52,589 |
March
28,
|
September
28,
|
|||||||
2008
|
2007
|
|||||||
Raw
material and parts
|
$ | 40,355 | $ | 40,725 | ||||
Work
in process
|
19,768 | 18,168 | ||||||
Finished
goods
|
6,738 | 8,554 | ||||||
$ | 66,861 | $ | 67,447 |
Six Months Ended
|
||||||||
March
28,
|
March
30,
|
|||||||
2008
|
2007
|
|||||||
Balance
at beginning of fiscal year
|
$ | 9,784 | $ | 8,822 | ||||
Inventory
provision, charged to cost of sales
|
550 | 540 | ||||||
Inventory
write-offs
|
(397 | ) | (218 | ) | ||||
Balance
at end of period
|
$ | 9,937 | $ | 9,144 |
Six Months Ended
|
||||||||
March
28,
|
March
30,
|
|||||||
2008
|
2007
|
|||||||
Balance
at beginning of fiscal year
|
$ | 2,700 | $ | 1,702 | ||||
Provision
for loss contracts, charged to
|
||||||||
cost
of sales
|
1,431 | 629 | ||||||
Reduction
upon revenue
|
||||||||
recognition
|
(2,096 | ) | (1,033 | ) | ||||
Balance
at end of period
|
$ | 2,035 | $ | 1,298 |
March
28,
|
March
30,
|
|||||||
2008
|
2007
|
|||||||
Inventories
|
$ | 953 | $ | 971 | ||||
Accrued
expenses
|
1,082 | 327 | ||||||
$ | 2,035 | $ | 1,298 |
Weighted Average Useful Life
(in years)
|
March 28, 2008
|
September 28, 2007
|
||||||||||||||||||||||||||
Cost
|
Accumulated Amortization
|
Net
|
Cost
|
Accumulated Amortization
|
Net
|
|||||||||||||||||||||||
VED
Core Technology
|
50
|
$ | 30,700 | $ | (2,580 | ) | $ | 28,120 | $ | 30,700 | $ | (2,273 | ) | $ | 28,427 | |||||||||||||
VED
Application Technology
|
25
|
19,800 | (3,317 | ) | 16,483 | 19,800 | (2,921 | ) | 16,879 | |||||||||||||||||||
X-ray
Generator and Satcom
|
||||||||||||||||||||||||||||
Application
Technology
|
15
|
8,000 | (2,241 | ) | 5,759 | 8,000 | (1,974 | ) | 6,026 | |||||||||||||||||||
Antenna
and Telemetry
|
||||||||||||||||||||||||||||
Technology
|
25
|
5,300 | (135 | ) | 5,165 | 5,300 | (29 | ) | 5,271 | |||||||||||||||||||
Customer
backlog
|
1
|
580 | (368 | ) | 212 | 580 | (78 | ) | 502 | |||||||||||||||||||
Land
lease
|
46
|
11,810 | (1,054 | ) | 10,756 | 11,810 | (928 | ) | 10,882 | |||||||||||||||||||
Tradename
|
Indefinite
|
7,600 | - | 7,600 | 7,600 | - | 7,600 | |||||||||||||||||||||
Customer
list and programs
|
25
|
6,280 | (817 | ) | 5,463 | 6,280 | (684 | ) | 5,596 | |||||||||||||||||||
Noncompete
agreement
|
5
|
640 | (144 | ) | 496 | 640 | (80 | ) | 560 | |||||||||||||||||||
Patent
application fees
|
-
|
147 | - | 147 | - | - | - | |||||||||||||||||||||
$ | 90,857 | $ | (10,656 | ) | $ | 80,201 | $ | 90,710 | $ | (8,967 | ) | $ | 81,743 |
Fiscal Year
|
Amount
|
|||
2008
(remaining six months)
|
$ | 1,615 | ||
2009
|
2,808 | |||
2010
|
2,786 | |||
2011
|
2,786 | |||
2012
|
2,772 | |||
Thereafter
|
59,834 | |||
$ | 72,601 |
Reportable Segments
|
||||||||||||||||
VED
|
Satcom
|
Other
|
Total
|
|||||||||||||
Balance
at September 28, 2007
|
$ | 132,897 | $ | 13,830 | $ | 14,846 | $ | 161,573 | ||||||||
Malibu
purchase price adjustment
|
- | - | 1,009 | 1,009 | ||||||||||||
Other
|
- | - | (47 | ) | (47 | ) | ||||||||||
Balance
at March 28, 2008
|
$ | 132,897 | $ | 13,830 | $ | 15,808 | $ | 162,535 |
Six Months Ended
|
||||||||
March
28,
|
March
30,
|
|||||||
2008
|
2007
|
|||||||
Balance
at beginning of fiscal year
|
$ | 5,578 | $ | 5,958 | ||||
Estimates
for product warranty, charged to cost of sales
|
1,406 | 2,374 | ||||||
Actual
costs of warranty claims
|
(2,032 | ) | (2,807 | ) | ||||
Balance
at end of period
|
$ | 4,952 | $ | 5,525 |
Net
current liabilities
|
$ | (3,938 | ) | |
Property,
plant and equipment
|
719 | |||
Deferred
tax liabilities
|
(703 | ) | ||
Identifiable
intangible assets
|
8,790 | |||
Goodwill
|
15,865 | |||
$ | 20,733 |
Weighted Average Useful Life
(in years)
|
Amount
|
|||||||
Non
compete agreements
|
5
|
$ | 530 | |||||
Tradename
|
Indefinite
|
|
1,800 | |||||
Antenna
and Telemetry technology
|
25
|
5,300 | ||||||
Backlog
|
1
|
580 | ||||||
Customer
relationships
|
15
|
580 | ||||||
$ | 8,790 |
March
28,
|
September 28,
|
|||||||
2008
|
2007
|
|||||||
Term
loan, expiring 2014
|
$ | 95,750 | $ | 99,750 | ||||
8%
Senior subordinated notes due 2012
|
125,000 | 125,000 | ||||||
Floating rate senior notes
due 2015, net of issue
discount of $127 and $183
|
15,873 | 21,817 | ||||||
236,623 | 246,567 | |||||||
Less: Current
portion
|
2,000 | 1,000 | ||||||
Long-term
portion
|
$ | 234,623 | $ | 245,567 | ||||
Standby
letters of credit
|
$ | 5,882 | $ | 3,725 |
Year
|
Optional
Redemption Price
|
|||
2008
|
104 | % | ||
2009
|
102 | % | ||
2010
and thereafter
|
100 | % |
Year
|
Optional
Redemption Price
|
|||
2007
|
103 | % | ||
2008
|
102 | % | ||
2009
|
101 | % | ||
2010
and thereafter
|
100 | % |
Fiscal Year
|
Term Loan
|
8% Senior
Subordinated Notes
|
Floating Rate
Senior Notes
|
Total
|
||||||||||||
2008
(remaining six months)
|
$ | 2,000 | $ | - | $ | - | $ | 2,000 | ||||||||
2009
|
- | - | - | - | ||||||||||||
2010
|
- | - | - | - | ||||||||||||
2011
|
93,750 | - | - | 93,750 | ||||||||||||
2012
|
- | 125,000 | - | 125,000 | ||||||||||||
Thereafter
|
- | - | 16,000 | 16,000 | ||||||||||||
$ | 95,750 | $ | 125,000 | $ | 16,000 | $ | 236,750 |
Fiscal
Year
|
Operating
Leases
|
|||
2008
(remaining six months)
|
$ | 992 | ||
2009
|
1,435 | |||
2010
|
1,175 | |||
2011
|
507 | |||
2012
|
392 | |||
Thereafter
|
3,094 | |||
Total
future minimum lease payments
|
$ | 7,595 |
Fiscal
Year
|
Purchase
Contracts
|
|||
2008
(remaining six months)
|
$ | 31,071 | ||
2009
|
5,966 | |||
2010
|
388 | |||
2011
|
307 | |||
Total
purchase commitments
|
$ | 37,732 |
8.
|
Stock-based
Compensation Plans
|
Oustanding Options
|
Exercisable Options
|
|||||||||||||||||||||||||||||||
Number of Shares
|
Weighted-Average Exercise
Price
|
Weighted-Average Remaining Contractual Term
(Years)
|
Aggregate Intrinsic Value
|
Number of Shares
|
Weighted-Average Exercise
Price
|
Weighted-Average Remaining Contractual Term
(Years)
|
Aggregate Intrinsic Value
|
|||||||||||||||||||||||||
Balance
at September 28, 2007
|
3,171,081 | $ | 5.61 | 6.58 | $ | 42,513 | 2,259,528 | $ | 3.00 | 5.98 | $ | 36,184 | ||||||||||||||||||||
Granted
|
208,750 | 16.79 | ||||||||||||||||||||||||||||||
Exercised
|
- | - | ||||||||||||||||||||||||||||||
Forfeited
or cancelled
|
- | - | ||||||||||||||||||||||||||||||
Balance
at March 28, 2008
|
3,379,831 | $ | 6.30 | 6.30 | $ | 17,585 | 2,488,350 | $ | 3.43 | 5.61 | $ | 16,658 |
Number
of Shares
|
Weighted-Average
Grant-Date Fair Value
|
|||||||
Nonvested
at September 28, 2007
|
11,466 | $ | 17.44 | |||||
Granted
|
114,461 | 15.22 | ||||||
Vested
|
(5,673 | ) | 17.62 | |||||
Forfeited
|
- | - | ||||||
Nonvested
at March 28, 2008
|
120,254 | $ | 15.32 |
|
Three Months Ended
|
Six Months Ended
|
||||||||||||||
March 28, 2008
|
March 30,
2007
|
March 28,
2008
|
March 30,
2007
|
|||||||||||||
Share-based
compensation cost recognized in the income
statement by caption:
|
||||||||||||||||
Cost
of sales
|
$ | 111 | $ | 63 | $ | 191 | $ | 102 | ||||||||
Research
and development
|
38 | 16 | 69 | 26 | ||||||||||||
Selling
and marketing
|
59 | 32 | 104 | 51 | ||||||||||||
General
and administrative
|
342 | 177 | 610 | 314 | ||||||||||||
$ | 550 | $ | 288 | $ | 974 | $ | 493 | |||||||||
Share-based
compensation cost capitalized in inventory
|
$ | 119 | $ | 63 | $ | 215 | $ | 107 | ||||||||
Share-based
compensation cost remaining in inventory at end of period
|
$ | 72 | $ | 36 | $ | 72 | $ | 36 | ||||||||
Share-based
compensation expense by type of award:
|
||||||||||||||||
Stock
options and stock purchase plan
|
$ | 433 | $ | 260 | $ | 807 | $ | 435 | ||||||||
Restricted
stock and restricted stock units
|
117 | 28 | 167 | 58 | ||||||||||||
$ | 550 | $ | 288 | $ | 974 | $ | 493 |
Three
Months Ended
|
Six
Months Ended
|
|||||||||||||||
March
28, 2008
|
March
30, 2007
|
March
28,
2008
|
March
30,
2007
|
|||||||||||||
Expected
term (in years)
|
*
|
|
5.99 | 6.25 | 6.24 | |||||||||||
Expected
volatility
|
*
|
49.33 | % | 41.20 | % | 49.33 | % | |||||||||
Risk-free
rate
|
*
|
4.73 | % | 3.82 | % | 4.56 | % | |||||||||
Dividend yield |
*
|
0 | % | 0 | % | 0 | % | |||||||||
*
No new stock options were issued during the three months ended March 28,
2008.
|
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
March 28, 2008
|
March 30,
2007
|
March 28,
2008
|
March 30,
2007
|
|||||||||||||
Weighted
average common shares outstanding -- Basic
|
16,387 | 16,253 | 16,379 | 16,161 | ||||||||||||
Effect
of dilutive stock options and nonvested restricted stock awards and
units
|
1,269 | 1,477 | 1,365 | 1,485 | ||||||||||||
Weighted
average common shares outstanding -- Diluted
|
17,656 | 17,730 | 17,744 | 17,646 |
Three
Months Ended
|
Six
Months Ended
|
|||||||||||||||
March
28,
|
March
30,
|
March
28,
|
March
30,
|
|||||||||||||
2008
|
2007
|
2008
|
2007
|
|||||||||||||
Sales
to external customers
|
||||||||||||||||
VED
|
$ | 73,744 | $ | 72,216 | $ | 137,734 | $ | 139,191 | ||||||||
Satcom
equipment
|
17,134 | 16,228 | 34,709 | 32,976 | ||||||||||||
Other
|
3,926 | - | 8,271 | - | ||||||||||||
$ | 94,804 | $ | 88,444 | $ | 180,714 | $ | 172,167 | |||||||||
Intersegment
product transfers
|
||||||||||||||||
VED
|
$ | 7,287 | $ | 4,582 | $ | 13,148 | $ | 9,705 | ||||||||
Satcom
equipment
|
14 | 9 | 63 | 9 | ||||||||||||
$ | 7,301 | $ | 4,591 | $ | 13,211 | $ | 9,714 | |||||||||
Capital
expenditures
|
||||||||||||||||
VED
|
$ | 502 | $ | 2,429 | $ | 1,344 | $ | 5,231 | ||||||||
Satcom
equipment
|
210 | 22 | 654 | 22 | ||||||||||||
Other
|
159 | 25 | 560 | 94 | ||||||||||||
$ | 871 | $ | 2,476 | $ | 2,558 | $ | 5,347 | |||||||||
EBITDA
|
||||||||||||||||
VED
|
$ | 18,647 | $ | 17,932 | $ | 32,287 | $ | 35,516 | ||||||||
Satcom
equipment
|
656 | 1,121 | 2,377 | 2,618 | ||||||||||||
Other
|
(3,460 | ) | (2,743 | ) | (6,899 | ) | (4,739 | ) | ||||||||
$ | 15,843 | $ | 16,310 | $ | 27,765 | $ | 33,395 |
March
28,
|
September
28,
|
|||||||
2008
|
2007
|
|||||||
Total
assets
|
||||||||
VED
|
$ | 333,284 | $ | 335,926 | ||||
Satcom
equipment
|
48,155 | 49,266 | ||||||
Other
|
85,986 | 91,030 | ||||||
|
$ | 467,425 | $ | 476,222 |
|
•
|
EBITDA
is a component of the measures used by the Company’s board of directors
and management team to evaluate the Company’s operating
performance;
|
|
•
|
the
Senior Credit Facilities contain a covenant that requires the Company to
maintain a senior secured leverage ratio that contains EBITDA as a
component, and the Company’s management team uses EBITDA to monitor
compliance with this covenant;
|
|
•
|
EBITDA
is a component of the measures used by the Company’s management team to
make day-to-day operating
decisions;
|
|
•
|
EBITDA
facilitates comparisons between the Company’s operating results and those
of competitors with different capital structures and therefore is a
component of the measures used by the Company’s management to facilitate
internal comparisons to competitors’ results and the Company’s industry in
general; and
|
|
•
|
the
payment of management bonuses is contingent upon, among other things, the
satisfaction by the Company of certain targets that contain EBITDA as a
component.
|
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
March 28,
2008
|
March 30,
2007
|
March 28,
2008
|
March 30,
2007
|
|||||||||||||
Net
income
|
$ | 6,154 | $ | 5,760 | $ | 8,664 | $ | 11,595 | ||||||||
Depreciation
and amortization
|
2,742 | 2,188 | 5,392 | 4,382 | ||||||||||||
Interest
expense, net
|
4,805 | 5,275 | 9,617 | 10,614 | ||||||||||||
Income
tax expense
|
2,142 | 3,087 | 4,092 | 6,804 | ||||||||||||
EBITDA
|
$ | 15,843 | $ | 16,310 | $ | 27,765 | $ | 33,395 |
March
28,
|
September
28,
|
|||||||
2008
|
2007
|
|||||||
United
States
|
$ | 50,526 | $ | 51,704 | ||||
Canada
|
14,247 | 14,308 | ||||||
Other
|
46 | 36 | ||||||
$ | 64,819 | $ | 66,048 |
March
28,
|
September
28,
|
|||||||
2008
|
2007
|
|||||||
United
States
|
$ | 114,221 | $ | 113,310 | ||||
Canada
|
48,314 | 48,263 | ||||||
$ | 162,535 | $ | 161,573 |
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
March 28,
2008
|
March 30,
2007
|
March 28,
2008
|
March 30,
2007
|
|||||||||||||
United
States
|
$ | 62,206 | $ | 52,577 | $ | 116,729 | $ | 102,081 | ||||||||
All
foreign countries
|
32,598 | 35,867 | 63,985 | 70,086 | ||||||||||||
Total
sales
|
$ | 94,804 | $ | 88,444 | $ | 180,714 | $ | 172,167 |
Parent
|
Issuer
|
Guarantor
|
Non-Guarantor
|
Consolidating
|
Consolidated
|
|||||||||||||||||||
(CPI
Int'l)
|
(CPI)
|
Subsidiaries
|
Subsidiaries
|
Eliminations
|
Total
|
|||||||||||||||||||
Assets
|
||||||||||||||||||||||||
Cash
and cash equivalents
|
$ | 184 | $ | 16,436 | $ | 800 | $ | 2,821 | $ | - | $ | 20,241 | ||||||||||||
Restricted
cash
|
- | - | 1,606 | 184 | - | 1,790 | ||||||||||||||||||
Accounts
receivable, net
|
- | 25,413 | 12,511 | 12,795 | - | 50,719 | ||||||||||||||||||
Inventories
|
- | 43,400 | 7,299 | 16,925 | (763 | ) | 66,861 | |||||||||||||||||
Deferred
tax assets
|
- | 9,260 | - | 688 | - | 9,948 | ||||||||||||||||||
Intercompany
receivable
|
- | 17,676 | 3,292 | 6,652 | (27,620 | ) | - | |||||||||||||||||
Prepaid
and other current assets
|
- | 2,371 | 835 | 581 | - | 3,787 | ||||||||||||||||||
Total
current assets
|
184 | 114,556 | 26,343 | 40,646 | (28,383 | ) | 153,346 | |||||||||||||||||
Property,
plant and equipment, net
|
- | 47,349 | 3,184 | 14,286 | - | 64,819 | ||||||||||||||||||
Deferred
debt issue costs, net
|
552 | 5,176 | - | - | - | 5,728 | ||||||||||||||||||
Intangible
assets, net
|
- | 57,550 | 14,683 | 7,968 | - | 80,201 | ||||||||||||||||||
Goodwill
|
- | 92,557 | 21,715 | 48,263 | - | 162,535 | ||||||||||||||||||
Other
long-term assets
|
- | 424 | 272 | 100 | - | 796 | ||||||||||||||||||
Intercompany
notes receivable
|
- | 1,035 | - | - | (1,035 | ) | - | |||||||||||||||||
Investment
in subsidiaries
|
176,007 | 97,861 | - | - | (273,868 | ) | - | |||||||||||||||||
Total
assets
|
$ | 176,743 | $ | 416,508 | $ | 66,197 | $ | 111,263 | $ | (303,286 | ) | $ | 467,425 | |||||||||||
Liabilities
and stockholders' equity
|
||||||||||||||||||||||||
Current
portion of long-term debt
|
$ | - | $ | 2,000 | $ | - | $ | - | $ | - | $ | 2,000 | ||||||||||||
Accounts
payable
|
249 | 10,874 | 2,860 | 7,866 | - | 21,849 | ||||||||||||||||||
Accrued
expenses
|
230 | 18,038 | 3,260 | 4,517 | - | 26,045 | ||||||||||||||||||
Product
warranty
|
- | 2,630 | 501 | 1,821 | - | 4,952 | ||||||||||||||||||
Income
taxes payable
|
- | (276 | ) | 203 | 5,173 | - | 5,100 | |||||||||||||||||
Advance
payments from customers
|
- | 6,698 | 3,841 | 1,116 | - | 11,655 | ||||||||||||||||||
Intercompany
payable
|
27,620 | - | - | - | (27,620 | ) | - | |||||||||||||||||
Total
current liabilities
|
28,099 | 39,964 | 10,665 | 20,493 | (27,620 | ) | 71,601 | |||||||||||||||||
Deferred
income taxes
|
- | 20,941 | - | 5,369 | - | 26,310 | ||||||||||||||||||
Intercompany
notes payable
|
- | - | - | 1,035 | (1,035 | ) | - | |||||||||||||||||
Long-term
debt, less current portion
|
15,873 | 218,750 | - | - | - | 234,623 | ||||||||||||||||||
Other
long-term liabilities
|
- | 1,923 | - | 197 | - | 2,120 | ||||||||||||||||||
Total
liabilities
|
43,972 | 281,578 | 10,665 | 27,094 | (28,655 | ) | 334,654 | |||||||||||||||||
Common
stock
|
165 | - | - | - | - | 165 | ||||||||||||||||||
Parent
investment
|
- | 55,967 | 43,824 | 57,919 | (157,710 | ) | - | |||||||||||||||||
Additional
paid-in capital
|
70,165 | - | - | - | - | 70,165 | ||||||||||||||||||
Accumulated
other comprehensive (loss) income
|
(2,265 | ) | (2,265 | ) | - | (220 | ) | 2,485 | (2,265 | ) | ||||||||||||||
Retained
earnings
|
64,706 | 81,228 | 11,708 | 26,470 | (119,406 | ) | 64,706 | |||||||||||||||||
Total
stockholders’ equity
|
132,771 | 134,930 | 55,532 | 84,169 | (274,631 | ) | 132,771 | |||||||||||||||||
Total
liabilities and stockholders' equity
|
$ | 176,743 | $ | 416,508 | $ | 66,197 | $ | 111,263 | $ | (303,286 | ) | $ | 467,425 |
Parent
|
Issuer
|
Guarantor
|
Non-Guarantor
|
Consolidating
|
Consolidated
|
|||||||||||||||||||
(CPI
Int'l)
|
(CPI)
|
Subsidiaries
|
Subsidiaries
|
Eliminations
|
Total
|
|||||||||||||||||||
Assets
|
||||||||||||||||||||||||
Cash
and cash equivalents
|
$ | 1,378 | $ | 16,518 | $ | 958 | $ | 1,620 | $ | - | $ | 20,474 | ||||||||||||
Restricted
cash
|
- | - | 1,945 | 310 | - | 2,255 | ||||||||||||||||||
Accounts
receivable, net
|
- | 25,857 | 10,816 | 15,916 | - | 52,589 | ||||||||||||||||||
Inventories
|
- | 43,949 | 7,092 | 17,084 | (678 | ) | 67,447 | |||||||||||||||||
Deferred
tax assets
|
- | 9,272 | 3 | 469 | - | 9,744 | ||||||||||||||||||
Intercompany
receivable
|
- | 23,323 | 2,076 | 2,725 | (28,124 | ) | - | |||||||||||||||||
Prepaid
and other current assets
|
- | 3,250 | 545 | 844 | - | 4,639 | ||||||||||||||||||
Total
current assets
|
1,378 | 122,169 | 23,435 | 38,968 | (28,802 | ) | 157,148 | |||||||||||||||||
Property,
plant and equipment, net
|
- | 48,327 | 3,382 | 14,339 | - | 66,048 | ||||||||||||||||||
Deferred
debt issue costs, net
|
795 | 5,738 | - | - | - | 6,533 | ||||||||||||||||||
Intangible
assets, net
|
- | 67,008 | 6,465 | 8,270 | - | 81,743 | ||||||||||||||||||
Goodwill
|
- | 107,462 | 5,848 | 48,263 | - | 161,573 | ||||||||||||||||||
Other
long-term assets
|
- | 3,077 | - | 100 | - | 3,177 | ||||||||||||||||||
Intercompany
notes receivable
|
- | 1,035 | - | - | (1,035 | ) | - | |||||||||||||||||
Investment
in subsidiaries
|
175,889 | 65,491 | - | - | (241,380 | ) | - | |||||||||||||||||
Total
assets
|
$ | 178,062 | $ | 420,307 | $ | 39,130 | $ | 109,940 | $ | (271,217 | ) | $ | 476,222 | |||||||||||
Liabilities
and stockholders' equity
|
||||||||||||||||||||||||
Current
portion of long-term debt
|
$ | - | $ | 1,000 | $ | - | $ | - | $ | - | $ | 1,000 | ||||||||||||
Accounts
payable
|
224 | 10,421 | 2,430 | 8,719 | - | 21,794 | ||||||||||||||||||
Accrued
expenses
|
404 | 16,695 | 3,991 | 5,259 | - | 26,349 | ||||||||||||||||||
Product
warranty
|
- | 3,141 | 481 | 1,956 | - | 5,578 | ||||||||||||||||||
Income
taxes payable
|
- | 1,888 | 562 | 6,298 | - | 8,748 | ||||||||||||||||||
Advance
payments from customers
|
- | 5,926 | 4,933 | 1,273 | - | 12,132 | ||||||||||||||||||
Intercompany
payable
|
28,124 | - | - | - | (28,124 | ) | - | |||||||||||||||||
Total
current liabilities
|
28,752 | 39,071 | 12,397 | 23,505 | (28,124 | ) | 75,601 | |||||||||||||||||
Deferred
income taxes
|
31 | 22,833 | - | 5,530 | - | 28,394 | ||||||||||||||||||
Intercompany
notes payable
|
- | - | - | 1,035 | (1,035 | ) | - | |||||||||||||||||
Long-term
debt, less current portion
|
21,817 | 223,750 | - | - | - | 245,567 | ||||||||||||||||||
Other
long-term liabilities
|
- | 547 | - | 207 | - | 754 | ||||||||||||||||||
Total
liabilities
|
50,600 | 286,201 | 12,397 | 30,277 | (29,159 | ) | 350,316 | |||||||||||||||||
Common
stock
|
164 | - | - | - | - | 164 | ||||||||||||||||||
Parent
investment
|
- | 60,705 | 19,167 | 57,746 | (137,618 | ) | - | |||||||||||||||||
Additional
paid-in capital
|
68,763 | - | - | - | - | 68,763 | ||||||||||||||||||
Accumulated
other comprehensive income
|
1,110 | 1,059 | - | 155 | (1,387 | ) | 937 | |||||||||||||||||
Retained
earnings
|
57,425 | 72,342 | 7,566 | 21,762 | (103,053 | ) | 56,042 | |||||||||||||||||
Total
stockholders’ equity
|
127,462 | 134,106 | 26,733 | 79,663 | (242,058 | ) | 125,906 | |||||||||||||||||
Total
liabilities and stockholders' equity
|
$ | 178,062 | $ | 420,307 | $ | 39,130 | $ | 109,940 | $ | (271,217 | ) | $ | 476,222 |
Parent
|
Issuer
|
Guarantor
|
Non-Guarantor
|
Consolidating
|
Consolidated
|
|||||||||||||||||||
(CPI
Int'l)
|
(CPI)
|
Subsidiaries
|
Subsidiaries
|
Eliminations
|
Total
|
|||||||||||||||||||
Sales
|
$ | - | $ | 60,336 | $ | 21,125 | $ | 34,490 | $ | (21,147 | ) | $ | 94,804 | |||||||||||
Cost
of sales
|
- | 42,877 | 17,891 | 27,079 | (21,109 | ) | 66,738 | |||||||||||||||||
Gross
profit
|
- | 17,459 | 3,234 | 7,411 | (38 | ) | 28,066 | |||||||||||||||||
Operating
costs and expenses:
|
||||||||||||||||||||||||
Research
and development
|
- | 729 | 272 | 1,929 | - | 2,930 | ||||||||||||||||||
Selling
and marketing
|
- | 2,070 | 1,175 | 2,083 | - | 5,328 | ||||||||||||||||||
General
and administrative
|
- | 3,817 | 1,018 | 657 | - | 5,492 | ||||||||||||||||||
Amortization
of acquisition-related
|
||||||||||||||||||||||||
intangible
assets
|
- | 100 | 531 | 150 | - | 781 | ||||||||||||||||||
Net
loss on disposition of assets
|
- | 22 | 10 | 9 | - | 41 | ||||||||||||||||||
Total
operating costs and expenses
|
- | 6,738 | 3,006 | 4,828 | - | 14,572 | ||||||||||||||||||
Operating
income
|
- | 10,721 | 228 | 2,583 | (38 | ) | 13,494 | |||||||||||||||||
Interest
expense (income), net
|
512 | 4,314 | (17 | ) | (4 | ) | - | 4,805 | ||||||||||||||||
Loss
on debt extinguishment
|
393 | - | - | - | - | 393 | ||||||||||||||||||
(Loss)
income before income tax expense
|
||||||||||||||||||||||||
and
equity in income of subsidiaries
|
(905 | ) | 6,407 | 245 | 2,587 | (38 | ) | 8,296 | ||||||||||||||||
Income
tax (benefit) expense
|
(344 | ) | 2,741 | (135 | ) | (120 | ) | - | 2,142 | |||||||||||||||
Equity
in income of subsidiaries
|
6,715 | 3,049 | - | - | (9,764 | ) | - | |||||||||||||||||
Net
income
|
$ | 6,154 | $ | 6,715 | $ | 380 | $ | 2,707 | $ | (9,802 | ) | $ | 6,154 |
Parent
|
Issuer
|
Guarantor
|
Non-Guarantor
|
Consolidating
|
Consolidated
|
|||||||||||||||||||
(CPI
Int'l)
|
(CPI)
|
Subsidiaries
|
Subsidiaries
|
Eliminations
|
Total
|
|||||||||||||||||||
Sales
|
$ | - | $ | 56,666 | $ | 16,351 | $ | 34,143 | $ | (18,716 | ) | $ | 88,444 | |||||||||||
Cost
of sales
|
- | 40,211 | 13,642 | 26,255 | (19,369 | ) | 60,739 | |||||||||||||||||
Gross
profit
|
- | 16,455 | 2,709 | 7,888 | 653 | 27,705 | ||||||||||||||||||
Operating
costs and expenses:
|
||||||||||||||||||||||||
Research
and development
|
- | 902 | - | 1,450 | - | 2,352 | ||||||||||||||||||
Selling
and marketing
|
- | 2,015 | 869 | 1,915 | - | 4,799 | ||||||||||||||||||
General
and administrative
|
- | 4,402 | 515 | 929 | - | 5,846 | ||||||||||||||||||
Amortization
of acquisition-related
|
||||||||||||||||||||||||
intangible
assets
|
- | 334 | 62 | 150 | - | 546 | ||||||||||||||||||
Net
loss on disposition of assets
|
- | 17 | - | 23 | - | 40 | ||||||||||||||||||
Total
operating costs and expenses
|
- | 7,670 | 1,446 | 4,467 | - | 13,583 | ||||||||||||||||||
Operating
income
|
- | 8,785 | 1,263 | 3,421 | 653 | 14,122 | ||||||||||||||||||
Interest
expense (income), net
|
2,072 | 3,328 | (9 | ) | (116 | ) | - | 5,275 | ||||||||||||||||
(Loss)
income before income tax expense
|
||||||||||||||||||||||||
and
equity in income of subsidiaries
|
(2,072 | ) | 5,457 | 1,272 | 3,537 | 653 | 8,847 | |||||||||||||||||
Income
tax (benefit) expense
|
(787 | ) | 2,650 | 356 | 868 | - | 3,087 | |||||||||||||||||
Equity
in income of subsidiaries
|
7,045 | 4,238 | - | - | (11,283 | ) | - | |||||||||||||||||
Net
income
|
$ | 5,760 | $ | 7,045 | $ | 916 | $ | 2,669 | $ | (10,630 | ) | $ | 5,760 |
Parent
|
Issuer
|
Guarantor
|
Non-Guarantor
|
Consolidating
|
Consolidated
|
|||||||||||||||||||
(CPI
Int'l)
|
(CPI)
|
Subsidiaries
|
Subsidiaries
|
Eliminations
|
Total
|
|||||||||||||||||||
Sales
|
$ | - | $ | 110,098 | $ | 40,951 | $ | 69,328 | $ | (39,663 | ) | $ | 180,714 | |||||||||||
Cost
of sales
|
- | 80,308 | 34,476 | 53,306 | (39,578 | ) | 128,512 | |||||||||||||||||
Gross
profit
|
- | 29,790 | 6,475 | 16,022 | (85 | ) | 52,202 | |||||||||||||||||
Operating
costs and expenses:
|
||||||||||||||||||||||||
Research
and development
|
- | 1,621 | 421 | 3,612 | - | 5,654 | ||||||||||||||||||
Selling
and marketing
|
- | 3,993 | 2,187 | 4,320 | - | 10,500 | ||||||||||||||||||
General
and administrative
|
- | 7,535 | 2,088 | 2,022 | - | 11,645 | ||||||||||||||||||
Amortization
of acquisition-related
|
||||||||||||||||||||||||
intangible
assets
|
- | 668 | 593 | 301 | - | 1,562 | ||||||||||||||||||
Net
loss on disposition of assets
|
- | 44 | 12 | 19 | - | 75 | ||||||||||||||||||
Total
operating costs and expenses
|
- | 13,861 | 5,301 | 10,274 | - | 29,436 | ||||||||||||||||||
Operating
income
|
- | 15,929 | 1,174 | 5,748 | (85 | ) | 22,766 | |||||||||||||||||
Interest
expense (income), net
|
1,057 | 8,599 | (37 | ) | (2 | ) | - | 9,617 | ||||||||||||||||
Loss
on debt extinguishment
|
393 | - | - | - | - | 393 | ||||||||||||||||||
(Loss)
income before income tax expense
|
||||||||||||||||||||||||
and
equity in income of subsidiaries
|
(1,450 | ) | 7,330 | 1,211 | 5,750 | (85 | ) | 12,756 | ||||||||||||||||
Income
tax (benefit) expense
|
(551 | ) | 3,482 | 119 | 1,042 | - | 4,092 | |||||||||||||||||
Equity
in income of subsidiaries
|
9,563 | 5,715 | - | - | (15,278 | ) | - | |||||||||||||||||
Net
income
|
$ | 8,664 | $ | 9,563 | $ | 1,092 | $ | 4,708 | $ | (15,363 | ) | $ | 8,664 |
Parent
|
Issuer
|
Guarantor
|
Non-Guarantor
|
Consolidating
|
Consolidated
|
|||||||||||||||||||
(CPI
Int'l)
|
(CPI)
|
Subsidiaries
|
Subsidiaries
|
Eliminations
|
Total
|
|||||||||||||||||||
Sales
|
$ | - | $ | 108,031 | $ | 30,931 | $ | 68,686 | $ | (35,481 | ) | $ | 172,167 | |||||||||||
Cost
of sales
|
- | 75,706 | 25,707 | 52,681 | (36,213 | ) | 117,881 | |||||||||||||||||
Gross
profit
|
- | 32,325 | 5,224 | 16,005 | 732 | 54,286 | ||||||||||||||||||
Operating
costs and expenses:
|
||||||||||||||||||||||||
Research
and development
|
- | 1,545 | - | 2,698 | - | 4,243 | ||||||||||||||||||
Selling
and marketing
|
- | 3,984 | 1,698 | 3,946 | - | 9,628 | ||||||||||||||||||
General
and administrative
|
- | 8,093 | 722 | 1,435 | - | 10,250 | ||||||||||||||||||
Amortization
of acquisition-related
|
||||||||||||||||||||||||
intangible
assets
|
- | 668 | 125 | 301 | - | 1,094 | ||||||||||||||||||
Net
loss on disposition of assets
|
- | 17 | - | 41 | - | 58 | ||||||||||||||||||
Total
operating costs and expenses
|
- | 14,307 | 2,545 | 8,421 | - | 25,273 | ||||||||||||||||||
Operating
income
|
- | 18,018 | 2,679 | 7,584 | 732 | 29,013 | ||||||||||||||||||
Interest
expense (income), net
|
4,120 | 6,619 | (15 | ) | (110 | ) | - | 10,614 | ||||||||||||||||
(Loss)
income before income tax expense
|
||||||||||||||||||||||||
and
equity in income of subsidiaries
|
(4,120 | ) | 11,399 | 2,694 | 7,694 | 732 | 18,399 | |||||||||||||||||
Income
tax (benefit) expense
|
(1,566 | ) | 5,221 | 737 | 2,412 | - | 6,804 | |||||||||||||||||
Equity
in income of subsidiaries
|
14,149 | 7,971 | - | - | (22,120 | ) | - | |||||||||||||||||
Net
income
|
$ | 11,595 | $ | 14,149 | $ | 1,957 | $ | 5,282 | $ | (21,388 | ) | $ | 11,595 |
Parent
|
Issuer
|
Guarantor
|
Non-Guarantor
|
Consolidating
|
Consolidated
|
|||||||||||||||||||
(CPI
Int'l)
|
(CPI)
|
Subsidiaries
|
Subsidiaries
|
Eliminations
|
Total
|
|||||||||||||||||||
Cash
flows from operating activities
|
||||||||||||||||||||||||
Net
cash (used in) provided by operating activities
|
$ | (1,812 | ) | $ | 1,779 | $ | 8,749 | $ | 1,723 | $ | - | $ | 10,439 | |||||||||||
Cash
flows from investing activities
|
||||||||||||||||||||||||
Capital
expenditures
|
- | (1,941 | ) | (95 | ) | (522 | ) | - | (2,558 | ) | ||||||||||||||
Proceeds
from adjustment to acquisition purchase price
|
- | 1,615 | - | - | - | 1,615 | ||||||||||||||||||
Payment
of patent application fees
|
- | - | (147 | ) | - | - | (147 | ) | ||||||||||||||||
Net
cash used in investing activities
|
- | (326 | ) | (242 | ) | (522 | ) | - | (1,090 | ) | ||||||||||||||
Cash
flows from financing activities
|
||||||||||||||||||||||||
Repayments
of debt
|
(6,000 | ) | (4,000 | ) | - | - | - | (10,000 | ) | |||||||||||||||
Proceeds
from issuance of common stock to employees
|
418 | - | - | - | - | 418 | ||||||||||||||||||
Intercompany
dividends
|
6,200 | (6,200 | ) | - | - | - | - | |||||||||||||||||
Net
cash provided by (used in) financing activities
|
618 | (10,200 | ) | - | - | - | (9,582 | ) | ||||||||||||||||
Net
(decrease) increase in cash and cash equivalents
|
(1,194 | ) | (8,747 | ) | 8,507 | 1,201 | - | (233 | ) | |||||||||||||||
Cash
and cash equivalents at beginning of period
|
1,378 | 16,518 | 958 | 1,620 | - | 20,474 | ||||||||||||||||||
Cash
and cash equivalents at end of period
|
$ | 184 | $ | 7,771 | $ | 9,465 | $ | 2,821 | $ | - | $ | 20,241 |
Parent
|
Issuer
|
Guarantor
|
Non-Guarantor
|
Consolidating
|
Consolidated
|
|||||||||||||||||||
(CPI
Int'l)
|
(CPI)
|
Subsidiaries
|
Subsidiaries
|
Eliminations
|
Total
|
|||||||||||||||||||
Cash
flows from operating activities
|
||||||||||||||||||||||||
Net
cash (used in) provided by operating activities
|
$ | (563 | ) | $ | 2,888 | $ | 239 | $ | 3,735 | $ | - | $ | 6,299 | |||||||||||
Cash
flows from investing activities
|
||||||||||||||||||||||||
Capital
expenditures
|
- | (1,634 | ) | (21 | ) | (3,692 | ) | - | (5,347 | ) | ||||||||||||||
Capitalized
expenses relating to potential business acquisition
|
- | (119 | ) | - | - | - | (119 | ) | ||||||||||||||||
Net
cash used in investing activities
|
- | (1,753 | ) | (21 | ) | (3,692 | ) | - | (5,466 | ) | ||||||||||||||
Cash
flows from financing activities
|
||||||||||||||||||||||||
Repayments
of debt
|
- | (5,000 | ) | - | - | - | (5,000 | ) | ||||||||||||||||
Proceeds
from issuance of common stock to employees
|
398 | - | - | - | - | 398 | ||||||||||||||||||
Proceeds
from exercise of stock options
|
542 | - | - | - | - | 542 | ||||||||||||||||||
Excess
tax benefit on stock option exercises
|
- | 679 | - | - | - | 679 | ||||||||||||||||||
Net
cash provided by (used in) financing activities
|
940 | (4,321 | ) | - | - | - | (3,381 | ) | ||||||||||||||||
Net
increase (decrease) in cash and cash equivalents
|
377 | (3,186 | ) | 218 | 43 | - | (2,548 | ) | ||||||||||||||||
Cash
and cash equivalents at beginning of period
|
139 | 28,299 | 290 | 1,425 | - | 30,153 | ||||||||||||||||||
Cash
and cash equivalents at end of period
|
$ | 516 | $ | 25,113 | $ | 508 | $ | 1,468 | $ | - | $ | 27,605 |
Six
Months Ended
|
||||||||||||||||||||||||
March
28, 2008
|
March
30, 2007
|
Increase
(Decrease)
|
||||||||||||||||||||||
%
of
|
%
of
|
|||||||||||||||||||||||
Amount
|
Orders
|
Amount
|
Orders
|
Amount
|
Percent
|
|||||||||||||||||||
Radar
and Electronic Warfare
|
$ | 70.7 | 38 | % | $ | 76.3 | 41 | % | $ | (5.6 | ) | (7 | ) % | |||||||||||
Medical
|
36.7 | 20 | 36.8 | 20 | (0.1 | ) | - | |||||||||||||||||
Communications
|
55.9 | 30 | 54.6 | 30 | 1.3 | 2 | ||||||||||||||||||
Industrial
|
14.3 | 8 | 10.6 | 6 | 3.7 | 35 | ||||||||||||||||||
Scientific
|
7.6 | 4 | 5.9 | 3 | 1.7 | 29 | ||||||||||||||||||
Total
|
$ | 185.2 | 100 | % | $ | 184.2 | 100 | % | $ | 1.0 | 1 | % |
·
|
Radar and Electronic
Warfare: The majority of our sales
in the radar and electronic warfare markets are for products for domestic
and international defense and government end uses. Orders in these markets
are characterized by many smaller orders in the $0.5 million to $3.0
million range by product or program, and the timing of these orders may
vary from year to year. On a combined basis, orders for the radar and
electronic warfare markets decreased approximately 7% from an aggregate of
$76.3 million in the six months ended March 30, 2007 to an aggregate of
$70.7 million in the six months ended March 28, 2008. The decrease in
orders for these combined markets primarily resulted from decreased demand
for radar products to support Aegis weapons system and continued delays in
the placement of orders, and was partially offset by radar orders received
by our recently acquired Malibu division.
Demand
for our products to support ships with the Aegis weapons system has two
components: we support new ship builds and we provide spare and repair
products for previously
fielded ships. Over the past several years, we have seen high demand for
products to support a significant number of new ship builds for the Aegis
weapons program for U.S. and international military customers. We have now
received all orders for our products required to support these new ship
builds. As a result, we expect the demand to be primarily for spare and
repair products and, therefore, at overall lower levels than in the past
several years. We expect demand for our products to increase again as the
new ships are commissioned, deployed and added to the installed base,
after which they will require spare and repair products.
During fiscal year 2008, we have been
experiencing delays in the receipt of orders for radar and electronic
warfare programs, which subsequently impacts the timing of our sales for
these programs, and we expect these delays to continue for the foreseeable
future.
|
·
|
Medical: Orders for
our medical products consist of orders for medical imaging applications,
such as x-ray imaging, positron emission tomography (“PET”) and magnetic
resonance imaging (“MRI”), and for radiation therapy applications for the
treatment of cancer. Order levels in this market were essentially
unchanged.
A
Russian tender program in which we participated in fiscal years 2006 and
2007 will not recur in fiscal year 2008. In the six months ended March 30,
2007, we received approximately $1.4 million of the fiscal year’s $5.8
million in orders for the Russian tender program. In the six months ended
March 28, 2008, the decrease in x-ray generator orders for this Russian
tender program was offset by growth in orders for x-ray generators for
international customers.
In
fiscal year 2007, demand for products for MRI applications was very
strong, as a large customer ordered a two-year supply of these products in
one fiscal year, and we shipped a significant amount of these products
during that fiscal year. As a result, in the first half of fiscal year
2008, orders for products for MRI applications decreased approximately
$2.2 million. This decrease was partially offset by an increase in orders
for products for radiation therapy
applications.
|
·
|
Communications: The
2% increase in communications orders was primarily attributable to
telemetry orders received by our recently acquired Malibu division, as
well as the receipt of our first production orders, totaling approximately
$3 million, for Increment One of the
|
|
Warfighter
Information Network Tactical (“WIN-T”) military communications program.
These increases were partially offset by a decrease in orders for certain
military communications programs, including WIN-T’s predecessor program,
the Joint Network Node (“JNN”) military communications program, for which
we had strong demand in the first six months of fiscal year 2007, and a
decrease in orders for direct-to-home broadcast applications due to order
timing. In the six months ended March 28, 2008, as the WIN-T program began
to ramp up for production, orders to support the predecessor JNN program
decreased $3.9 million due the completion of that program. Once
the WIN-T program is fully ramped up for production, we expect that our
overall participation levels in the WIN-T program will be significantly
higher than our participation levels in the previous JNN
program.
|
·
|
Industrial: Orders in
the industrial market are cyclical. The $3.7 million increase in
industrial orders was attributable to orders for products used in a wide
variety of industrial applications, including industrial fabrication
applications, international test systems and food processing, cargo
screening and other industrial
applications.
|
·
|
Scientific: Orders in
the scientific market are historically one-time projects and can fluctuate
significantly from period to period. The $1.7 million increase in
scientific orders was primarily the result of orders for products to
support a new accelerator project for fusion research at an international
scientific institute. This increase was partially offset by
decreases in orders for certain other scientific programs due to the
timing of orders for those
programs.
|
Three
Months Ended
|
||||||||||||||||||||
March
28, 2008
|
March
30, 2007
|
Increase
(Decrease)
|
||||||||||||||||||
Amount
|
%
of Sales
|
Amount
|
%
of Sales
|
Amount
|
||||||||||||||||
Sales
|
$ | 94.8 | 100.0 | % | $ | 88.4 | 100.0 | % | $ | 6.4 | ||||||||||
Cost
of sales
|
66.7 | 70.4 | 60.7 | 68.7 | 6.0 | |||||||||||||||
Gross
profit
|
28.1 | 29.6 | 27.7 | 31.3 | 0.4 | |||||||||||||||
Research
and development
|
2.9 | 3.1 | 2.4 | 2.7 | 0.5 | |||||||||||||||
Selling
and marketing
|
5.3 | 5.6 | 4.8 | 5.4 | 0.5 | |||||||||||||||
General
and administrative
|
5.5 | 5.8 | 5.8 | 6.6 | (0.3 | ) | ||||||||||||||
Amortization
of acquisition-
|
||||||||||||||||||||
related
intangibles
|
0.8 | 0.8 | 0.5 | 0.6 | 0.3 | |||||||||||||||
Net
loss on disposition of assets
|
- | - | - | - | - | |||||||||||||||
Operating
income
|
13.5 | 14.2 | 14.1 | 16.0 | (0.6 | ) | ||||||||||||||
Interest
expense, net
|
4.8 | 5.1 | 5.3 | 6.0 | (0.5 | ) | ||||||||||||||
Loss
on debt extinguishment
|
0.4 | 0.4 | - | 0.0 | 0.4 | |||||||||||||||
Income
before taxes
|
8.3 | 8.7 | 8.8 | 10.0 | (0.5 | ) | ||||||||||||||
Income
tax expense
|
2.1 | 2.2 | 3.1 | 3.5 | (1.0 | ) | ||||||||||||||
Net
income
|
$ | 6.2 | 6.5 | % | $ | 5.8 | 6.6 | % | $ | 0.4 | ||||||||||
Other
Data:
|
||||||||||||||||||||
EBITDA
(a)
|
$ | 15.8 | 16.7 | % | $ | 16.3 | 18.4 | % | $ | (0.5 | ) |
Note: Totals
may not equal the sum of the component line items due to independent
rounding. Percentages are calculated based on rounded dollar amounts
presented.
|
(a)
|
EBITDA
represents earnings before provision for income taxes, net interest
expense and depreciation and amortization. For the reasons listed below,
we believe that GAAP-based financial information for leveraged businesses
such as ours should be supplemented by EBITDA so that investors better
understand our financial performance in connection with their analysis of
our business:
|
|
•
|
EBITDA
is a component of the measures used by our board of directors and
management team to evaluate our operating
performance;
|
|
•
|
our
senior credit facilities contain covenants that require us to maintain
certain interest expense coverage and leverage ratios that contain EBITDA
as a component, and our management team uses EBITDA to monitor compliance
with such covenants;
|
|
•
|
EBITDA
is a component of the measures used by our management team to make
day-to-day operating decisions;
|
|
•
|
EBITDA
facilitates comparisons between our operating results and those of
competitors with different capital structures and therefore is a component
of the measures used by the management to facilitate internal comparisons
to competitors' results and our industry in general;
and
|
|
•
|
the
payment of management bonuses is contingent upon, among other things, the
satisfaction by us of certain targets that contain EBITDA as a
component.
|
Three
Months Ended
|
||||||||||||||||||||||||
March
28, 2008
|
March
30, 2007
|
Increase
(Decrease)
|
||||||||||||||||||||||
Amount
|
%
of Sales
|
Amount
|
%
of Sales
|
Amount
|
Percent
|
|||||||||||||||||||
Radar
and Electronic Warfare
|
$ | 40.5 | 43 | % | $ | 36.3 | 41 | % | $ | 4.2 | 12 | % | ||||||||||||
Medical
|
17.1 | 18 | 17.0 | 19 | 0.1 | 1 | ||||||||||||||||||
Communications
|
27.6 | 29 | 27.0 | 31 | 0.6 | 2 | ||||||||||||||||||
Industrial
|
6.6 | 7 | 6.4 | 7 | 0.2 | 3 | ||||||||||||||||||
Scientific
|
3.0 | 3 | 1.7 | 2 | 1.3 | 76 | ||||||||||||||||||
Total
|
$ | 94.8 | 100 | % | $ | 88.4 | 100 | % | $ | 6.4 | 7 | % |
·
|
Radar and Electronic
Warfare: The majority of our sales in the radar and electronic
warfare markets are for products for domestic and international defense
and government end uses. The timing of orders receipts and
subsequent shipments in these markets may vary from year to
year. On a combined basis, sales for these two markets
increased approximately 12% from $36.3 million in the second quarter of
fiscal year 2007 to $40.5 million in the second quarter of fiscal year
2008, primarily due to increased sales of radar products to support the
HAWK missile system and other military and weather radar systems, as well
as sales of radar products by our recently acquired Malibu
division.
|
·
|
Medical: Sales of our
medical products consist of sales for medical imaging applications, such
as x-ray imaging, PET and MRI, and for radiation therapy applications for
the treatment of cancer. Sales levels in this market were essentially
unchanged.
|
|
A
Russian tender program in which we participated in fiscal years 2006 and
2007 will not recur in fiscal year 2008. The $0.6 million decrease in
x-ray generator sales for this Russian tender program was offset by growth
in sales for x-ray generators for international customers. We are
beginning to see some softening in demand for x-ray generators for U.S.
customers due to the impact of the phasing in of the Deficit Reduction Act
of 2005 and currently challenging credit conditions.
In fiscal year 2007, demand for products for
MRI applications was very strong, as a large customer ordered a two-year
supply of these products in one fiscal year, and we shipped a significant
amount of these products during that fiscal year. As a result, in the
second quarter of fiscal year 2008, sales of products for MRI applications
decreased approximately $0.4
million.
|
·
|
Communications: The
2% increase in sales in the communications market was primarily the result
of sales of telemetry products by our recently acquired Malibu division,
as well as the start of our first production shipments for Increment One
of the WIN-T military communications program and increased sales of
satellite communications products for certain foreign broadcast network
applications and military communications programs. These increases were
partially offset by a decrease in sales of products for domestic
direct-to-home applications as well as certain military communications
programs, including the JNN program, for which we had strong sales in the
three months ended March 30, 2007. In the three months ended March 28,
2008, we shipped $1.7 million in products to support the WIN-T military
communications program as it began to ramp up for production. These sales
were offset by a $1.7 million decrease in sales of products to support its
predecessor, the JNN military communications program due to the completion
of that program. We expect that our overall participation levels in the
WIN-T program will be significantly higher than our participation levels
in the previous JNN program.
|
·
|
Industrial: Sales in the
industrial market are cyclical. The $0.2 million increase in industrial
sales was due to sales of products used in a wide variety of industrial
applications.
|
·
|
Scientific: Sales
in the scientific market are historically one-time projects and can
fluctuate significantly from period to period. The $1.3 million increase
in scientific sales was primarily the result of increased product
shipments for the Spallation Neutron Source at Oakridge National
Laboratory. We received approximately $5 million in orders for this
program in fiscal year 2007 and expect to complete our shipments of
products for this program in the second quarter of fiscal year
2009.
|
Six
Months Ended
|
||||||||||||||||||||
March
28, 2008
|
March
30, 2007
|
Increase
(Decrease)
|
||||||||||||||||||
Amount
|
%
of Sales
|
Amount
|
%
of Sales
|
Amount
|
||||||||||||||||
Sales
|
$ | 180.7 | 100.0 | % | $ | 172.2 | 100.0 | % | $ | 8.5 | ||||||||||
Cost
of sales
|
128.5 | 71.1 | 117.9 | 68.5 | 10.6 | |||||||||||||||
Gross
profit
|
52.2 | 28.9 | 54.3 | 31.5 | (2.1 | ) | ||||||||||||||
Research
and development
|
5.7 | 3.2 | 4.2 | 2.4 | 1.5 | |||||||||||||||
Selling
and marketing
|
10.5 | 5.8 | 9.6 | 5.6 | 0.9 | |||||||||||||||
General
and administrative
|
11.6 | 6.4 | 10.3 | 6.0 | 1.3 | |||||||||||||||
Amortization
of acquisition-
|
||||||||||||||||||||
related
intangibles
|
1.6 | 0.9 | 1.1 | 0.6 | 0.5 | |||||||||||||||
Net
loss on disposition of assets
|
0.1 | 0.1 | 0.1 | 0.1 | - | |||||||||||||||
Operating
income
|
22.8 | 12.6 | 29.0 | 16.8 | (6.2 | ) | ||||||||||||||
Interest
expense, net
|
9.6 | 5.3 | 10.6 | 6.2 | (1.0 | ) | ||||||||||||||
Loss
on debt extinguishment
|
0.4 | 0.2 | - | 0.0 | 0.4 | |||||||||||||||
Income
before taxes
|
12.8 | 7.1 | 18.4 | 10.7 | (5.6 | ) | ||||||||||||||
Income
tax expense
|
4.1 | 2.3 | 6.8 | 3.9 | (2.7 | ) | ||||||||||||||
Net
income
|
$ | 8.7 | 4.8 | % | $ | 11.6 | 6.7 | % | $ | (2.9 | ) | |||||||||
Other
Data:
|
||||||||||||||||||||
EBITDA
(a)
|
$ | 27.8 | 15.4 | % | $ | 33.4 | 19.4 | % | $ | (5.6 | ) |
(a)
|
EBITDA
represents earnings before provision for income taxes, net interest
expense and depreciation and amortization. For the reasons listed below,
we believe that GAAP-based financial information for leveraged businesses
such as ours should be supplemented by EBITDA so that investors
better understand our financial performance in connection with their
analysis of our business:
|
|
•
|
EBITDA
is a component of the measures used by our board of directors and
management team to evaluate our operating
performance;
|
|
•
|
our
senior credit facilities contain covenants that require us to maintain
certain interest expense coverage and leverage ratios that contain EBITDA
as a component, and our management team uses EBITDA to monitor compliance
with such covenants;
|
|
•
|
EBITDA
is a component of the measures used by our management team to make
day-to-day operating decisions;
|
|
•
|
EBITDA
facilitates comparisons between our operating results and those of
competitors with different capital structures and therefore is a component
of the measures used by the management to facilitate internal comparisons
to competitors' results and our industry in general;
and
|
|
•
|
the
payment of management bonuses is contingent upon, among other things, the
satisfaction by us of certain targets that contain EBITDA as a
component.
|
|
Other
companies may define EBITDA differently and, as a result, our measure of
EBITDA may not be directly comparable to EBITDA of other companies.
Although we use EBITDA as a financial measure to assess the performance of
our business, the use of EBITDA is limited because it does not include
certain material costs, such as interest and taxes, necessary to operate
our business. When analyzing our performance, EBITDA should be considered
in addition to, and not as a substitute for, net income, cash flows from
operating activities or other statements of operations or statements of
cash flows data prepared in accordance with
GAAP.
|
Six
Months Ended
|
||||||||||||||||||||||||
March
28, 2008
|
March
30, 2007
|
Increase
(Decrease)
|
||||||||||||||||||||||
Amount
|
%
of Sales
|
Amount
|
%
of Sales
|
Amount
|
Percent
|
|||||||||||||||||||
Radar
and Electronic Warfare
|
$ | 75.9 | 42 | % | $ | 70.3 | 40 | % | $ | 5.6 | 8 | % | ||||||||||||
Medical
|
32.7 | 18 | 34.1 | 20 | (1.4 | ) | (4 | ) | ||||||||||||||||
Communications
|
54.4 | 30 | 53.1 | 31 | 1.3 | 2 | ||||||||||||||||||
Industrial
|
12.1 | 7 | 11.4 | 7 | 0.7 | 6 | ||||||||||||||||||
Scientific
|
5.6 | 3 | 3.3 | 2 | 2.3 | 70 | ||||||||||||||||||
Total
|
$ | 180.7 | 100 | % | $ | 172.2 | 100 | % | $ | 8.5 | 5 | % |
·
|
Radar and Electronic
Warfare: The majority of our sales in the radar and electronic
warfare markets are for products for domestic and international defense
and government end uses. The timing of orders receipts and subsequent
shipments in these markets may vary from year to year. On a
combined basis, sales for these two markets increased approximately 8%
from $70.3 million in the six months ended March 30, 2007 to $75.9 million
in the corresponding period of fiscal year 2008. The increase in sales was
due primarily to sales of radar products by our recently acquired Malibu
division and increased sales to support the HAWK missile system and other
radar systems.
|
·
|
Medical: Sales of our
medical products consist of sales for medical imaging applications, such
as x-ray imaging, PET and MRI, and for radiation therapy applications for
the treatment of cancer. The 4% decrease in sales of our medical products
was primarily due to decreased sales of our products used in radiation
therapy and decreased sales of our products used in MRI applications. The
decrease in sales of radiation therapy products was primarily in the first
quarter of fiscal year 2008. As expected, we received our annual large
order for these radiation therapy products from a significant customer in
the second quarter of fiscal year 2008.
In fiscal year 2007, demand for products for
MRI applications was very strong, as a large customer ordered a two-year
supply of these products in that year, and we shipped a significant
amount of these products during that fiscal year. As a result, in the
first six months of fiscal year 2008, sales of products for MRI
applications decreased approximately $1.0
million.
|
|
A Russian tender program in which we
participated in fiscal years 2006 and 2007 will not recur in fiscal year
2008. The decrease in x-ray generator sales for this Russian tender
program was offset by growth in sales for x-ray generators for
international customers. We are beginning to see some softening in demand
for x-ray generators for U.S. customers due the impact of the phasing in
of the Deficit Reduction Act of 2005 and currently challenging credit
conditions, and sales of x-ray generators for U.S. customers in the first
six months of fiscal year 2008 were $0.7 million lower than in the first
six months of fiscal year
2007.
|
·
|
Communications: The
2% increase in sales in the communications market was primarily the result
of sales of telemetry products by our recently acquired Malibu division,
as well as the start of our first production shipments for Increment One
of the WIN-T military communications program and increased sales of
satellite communications products for certain foreign broadcast network
applications and military communications programs. These increases were
partially offset by a decrease in sales of products for certain military
communications programs, including the JNN program, certain foreign
broadcast network applications and domestic direct-to-home applications
for which we had strong sales in the first six months of fiscal year
2007.
In
the six months ended March 28, 2008, the $1.7 million increase in sales of
products to support the WIN-T military communications program as it began
to ramp up for production was offset by a $2.4 million decrease in sales
of products to support its predecessor, the JNN military communications
program. We expect that our overall participation levels in the WIN-T
program will be significantly higher than our participation levels in the
previous JNN program.
|
·
|
Industrial: Sales in the
industrial market are cyclical. The $0.7 million increase in
industrial sales was due to sales of products used a wide variety of
industrial applications.
|
·
|
Scientific: Sales
in the scientific market are historically one-time projects and can
fluctuate significantly from period to period. The $2.3 million increase
in scientific sales was primarily the result of increased product
shipments for the Spallation Neutron Source at Oakridge National
Laboratory. We received approximately $5 million in orders for this
program in fiscal year 2007 and expect to complete our shipments of
products for this program in the second quarter of fiscal year
2009.
|
March
28,
2008
|
September
28,
2007
|
|||||||
Cash
and cash equivalents
|
$ | 20,241 | $ | 20,474 | ||||
Working
capital
|
81,745 | 81,547 |
Nominee
|
For Votes
|
Withheld Votes
|
||||||
Michael
Targoff
|
14,002,823 | 1,958,641 | ||||||
William
P. Rutledge
|
15,728,762 | 232,702 |
Votes
|
Shares
|
|||
For
|
15,799,572 | |||
Against
|
101,592 | |||
Abstain
|
60,300 |
No.
|
Description
|
31.1
|
Certification
of Chief Executive Officer pursuant to Rule 13a-15(e) and Rule 15d-15(e),
promulgated under the Securities Exchange Act of 1934, as
amended.
|
31.2
|
Certification
of Chief Financial Officer pursuant to Rule 13a-15(e) and Rule 15d-15(e),
promulgated under the Securities Exchange Act of 1934, as
amended.
|
32.1
|
Certifications
of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
|
32.2
|
Certifications
of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
|
Dated:
May 7, 2008
|
/s/ JOEL A. LITTMAN
|
Joel
A. Littman
Chief
Financial Officer, Treasurer and Secretary
(Duly
Authorized Officer and Chief Financial
Officer)
|